What is Immunome's non-cash lease expense?

Immunome (IMNM) reported non-cash lease expense of $150K in Q1 2026.

How has Immunome's non-cash lease expense changed year-over-year?

Immunome's non-cash lease expense increased by 30.4% year-over-year, from $115K to $150K.

What is the long-term trend for Immunome's non-cash lease expense?

Over 3 years (2022 to 2025), Immunome's non-cash lease expense has grown at a 32.8% compound annual growth rate (CAGR), from $209K to $489K.

What does non-cash lease expense mean?

Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.

Immunome IMNM Non-Cash Lease Expense

Non-Cash Lease Expense at other companies

Arcus BiosciencesRCUS

$2M0.0%

SELLAS Life Sciences Group, Inc.SLS

$153K+4.1%

IDEAYA Biosciences, Inc.IDYA

$455K-14.6%

Immunovant, Inc.IMVT

$26K+18.2%

Crinetics PharmaceuticalsCRNX

$703K-13.5%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's non-cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's non-cash lease expense?: Immunome (IMNM) reported non-cash lease expense of $150K in Q1 2026.
How has Immunome's non-cash lease expense changed year-over-year?: Immunome's non-cash lease expense increased by 30.4% year-over-year, from $115K to $150K.
What is the long-term trend for Immunome's non-cash lease expense?: Over 3 years (2022 to 2025), Immunome's non-cash lease expense has grown at a 32.8% compound annual growth rate (CAGR), from $209K to $489K.
What does non-cash lease expense mean?: Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.